pharmacology

Latest

pharmacology

·June 16, 2020

Inexpensive steroid reduces death in severe coronavirus patients

Dexamethasone, an inexpensive steroid, reduced death by one-third in ventilated COVID-19 patients, and by one fifth in patients receiving oxygen for severe coronavirus symptoms. Preliminary findings suggest one death per eight patients ventilated could be prevented by administering dexamethasone. Read More

Featured Neuroscience Open Neuroscience Articles

·June 5, 2020

Widely available indigestion drug may curb COVID-19 symptoms in mild to moderate disease

Famotidine (Pepcid AC), an over-the-counter medication used to treat indigestion, shows promise as a potential treatment for COVID-19. Read More

Featured Neuroscience

·May 24, 2020

Preventing ‘cytokine storm’ may ease severe COVID-19 symptoms

Treating coronavirus patients with alpha-blockers may help prevent the cytokine storm associated with severe COVID-19 infection. Alpha-blockers interfere with the cell signaling that triggers cytokine storms. Mice with bacterial infections that were treated with alpha-blockers experienced reduced cytokine storms and decreased death rates. Read More

Featured Neuroscience Open Neuroscience Articles

·May 18, 2020

Antiviral drug can speed up recovery of COVID-19 patient

Interferon-a2b an antiviral treatment shows promise in helping to speed up the recovery of patients with severe COVID-19 infections. IFN-a2b improves viral clearance and decreases the levels of inflammatory markers in coronavirus patients. Read More

Featured Neuroscience Open Neuroscience Articles

·May 14, 2020

Evidence Does Not Support Chloroquine or HCQ Use Alone or in Combination with Azithromycin as Prophylaxis for COVID-19

Researchers find no beneficial evidence to support the use of chloroquine or hydroxychloroquine, either used alone or in combination with azithromycin, for the treatment of COVID-19. Read More

Featured Neuroscience Open Neuroscience Articles

·May 14, 2020

Arthritis drug Anakinra may improve respiratory function in some patients with severe COVID-19

Anakinra, a clinically approved anti-inflammatory used to treat rheumatoid arthritis, improves respiratory function in patients with severe COVID-19 infection. Read More

This shows someone holding a box of actemra

Featured Neurology Neuroscience

·May 3, 2020

Arthritis Drug Presents Promise as Treatment for COVID-19 Pneumonia

UCSD has launched a Phase III clinical trial to assess whether tocilizumab (Actemra), a drug commonly prescribed for rheumatoid arthritis and other inflammatory disorders, has therapeutic value for those at risk of developing severe COVID-19 infection. The drug is a monoclonal antibody-based therapy that blocks receptors for interleukin-6, a cytokine that triggers inflammation as an early immune response to coronavirus. Blocking IL-6 could prevent the risk of the COVID-19 associated cytokine storm many with severe infection experience. Read More

Featured Neuroscience Open Neuroscience Articles

·May 1, 2020

Scientists uncover structural basis for SARS-CoV-2 inhibition by Remdesivir

Researchers have identified the structural basis for SARS-CoV-2 inhibition by the drug Remdesivir. The findings reveal a potential binding pattern that offers support for the design of new, more efficient, and specific anti-COVID-19 drugs. Read More

Featured Neuroscience

·April 30, 2020

Experts warn against malarial drugs as a cure for coronavirus

Researchers warn early encouraging signals from small-scale preliminary trials for the use of hydroxychloroquine to treat coronavirus should be taken with caution. Current evidence suggests chloroquine and hydroxychloroquine can not be used as a general treatment for all COVID-19 infections. Researchers say the medications should be restricted for the treatment of COVID-19 patients with pneumonia and high death risk, and only then as part of a clinical trial. The study also points out the negative side effects produced by the anti-malarial drugs and warns that those who need the medication to treat Lupus might not have access to treatment if widespread use for coronavirus occurs. The study reports there is no evidence to support the mass use of chloroquine or hydroxychloroquine to prevent infection from occurring. Read More

Featured Neuroscience Open Neuroscience Articles

·April 25, 2020

Novel Compounds Designed To Inhibit SARS-CoV-2 Main Protease

Researchers have developed two new compounds that are able to inhibit SARS-CoV-2 main protease. The study reports one of the compounds is a strong drug candidate for further investigative trials in the treatment of coronavirus. Read More

Featured Genetics Neuroscience

·April 24, 2020

Asthma drug in clinical trial to treat severe COVID-19 patients

A new clinical trial is underway to test ibudilast, an asthma drug approved in Japan, for the treatment of severe COVID-19. Ibudilast is a MIF inhibitor. MIF is a gene that regulates immune response and is a driver of inflammation which results in the cytokine storm associated with coronavirus. Read More

Featured Neuroscience

·April 20, 2020

Remdesivir prevents disease progression in monkeys with COVID-19

Macaque monkeys infected with mild-to-moderate coronavirus responded well to the antiviral Remdesivir. Researchers report the monkeys showed reduced clinical symptoms and less lung damage when the drug was administered. The findings back up other reports which claim the drug is effective at treating human COVID-19 infections in current clinical trials. Read More

1 2 3 … 18